unev look forward tripl
top-lin bottom line beat guidanc re-affirmed
report non-gaap ep beat consensu total cystic
fibrosi cf product revenu beat consensu grow y-o-i
driven uptak symdeko off-set slight miss orkambi kalydeco sale
opex lower consensu re-affirmed guidanc total cf product
sale combin non-gaap sg expens
negoti uk franc still on-going secur reimburs updat
earn estim
symdeko sale beat off-set orkambi kalydeco miss
combin orkambi symdeko sale beat consensu
repres growth q/q symdeko sale beat consensu
orkambi sale miss consensu growth symdeko
driven switch patient orkambi nave patient note kalydeco sale
consensu expect still room
symdeko uptak orkambi-nav patient remain confid high
complianc rate patient take symdeko
tripl data receiv fast track
expect final phase result base tripl
combin avail nda submiss chosen tripl
combin expect submiss addit
initi phase studi next-gener corrector combin
tezacaftor potenti once-daili tripl combin regimen beyond cf
continu make progress multipl program includ pain sickl cell diseas
scd antitrypsin defici particularli vrtx candid
receiv fast track design fda enter
clinic healthi volunt plan begin clinic studi second
corrector under-perform broad market ytd vs
mani investor believ peak commerci opportun cf
franchis fairli reflect current stock price howev see upsid pipelin
particularli program resembl cf market underli patholog
market size reiter buy po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
vertex biopharmaceut compani focus
discoveri develop market new
therapi treatment cystic fibrosi
posit view believ
remain leader cystic fibrosi treatment
multipl posit readout next-gener
tripl combin allow penetr
price object base probability-adjust npv analysi
cash flow use wacc deriv follow valu
kalydeco orkambi tez/iva tripl combin homozyg
patient tripl combin heterozyg patient
inclus net cash
downsid risk price object slower expect launch orkambi
lower price increment price pressur failur phase trial tripl
combin addit pipelin setback upsid risk quicker
expect uptak orkambi better expect pricing/compli orkambi
quicker develop tripl combo heterozyg patient
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
